| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	https://ppubs.uspto.gov/api/pdf/downloadPdf/12448389?requestToken=eyJzdWIiOiJlZWQ3ZTE2MS1kZjI1LTQyNTktODVjNy02NmE4NGMzYWM1ZDciL...
 
																	HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...
 
																	JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...
 
																	 
																	
 
																	Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...
 
																	HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...
 
																	JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...
 
																	HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...